Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2023 | Current standard treatment options for pStage III gastric or G/GEJ cancer

Masanori Terashima • 3 Jun 2023
ASCO 2023
Gastric Cancer Gastroesophageal Cancer Gastrointestinal Cancer Docetaxel S-1
ATTRACTION-5

Masanori Terashima, MD, PhD, FACS, Shizuoka Cancer Center, Nagaizumi, Japan, discusses the current standard treatment options for postoperative adjuvant therapy in pathologic stage III gastric or gastroesophageal junction (G/GEJ) cancer. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Masanori Terashima

0:33
Subgroup analysis of ATTRACTION-5: benefit of nivolumab in G/GEJ advanced + PD-L1-positive tumors
Masanori Terashima • 3 Jun 2023
1:11
ATTRACTION-5: nivo + chemo as postoperative adju treatment for pathological stage III G/GEJ cancer
Masanori Terashima • 3 Jun 2023

Related Videos

1:53
Important pathophysiological determinants of elevated cirDNA post-surgery
Alain Thierry • 9 Apr 2024
0:47
Emerging molecular drivers and biomarker targets in gastroesophageal cancers
Tatsuhiro Shibata • 9 Apr 2024
0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals